Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?

Immune checkpoint inhibitors (ICIs) are beginning to show promise in the clinical management of hepatocellular carcinoma (HCC). Most recently, the anti-programmed death protein-1 (PD-1) agent atezolizumab combined with bevacizumab demonstrated superiority to sorafenib in a Phase 3 randomised clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Tovoli, Francesco, De Lorenzo, Stefania, Trevisani, Franco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711845/
https://www.ncbi.nlm.nih.gov/pubmed/33023131
http://dx.doi.org/10.3390/vaccines8040578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711845/
https://www.ncbi.nlm.nih.gov/pubmed/33023131
http://dx.doi.org/10.3390/vaccines8040578

Ejemplares similares